Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes: A retrospective cohort study

Concerns about the cardiovascular safety of dipeptidyl peptidase-4 (DPP-4) inhibitors persist. This study sought to determine whether there is a differential risk of hospitalization for cardiovascular diseases (CVDs) between DPP-4 inhibitors and glimepiride. We conducted this retrospective cohort st...

Descripción completa

Detalles Bibliográficos
Autores principales: Chin, Hyouk-Jun, Nam, Jin Hyun, Lee, Eui-Kyung, Shin, Ju-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
4300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484219/
https://www.ncbi.nlm.nih.gov/pubmed/28640111
http://dx.doi.org/10.1097/MD.0000000000007213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484219/
https://www.ncbi.nlm.nih.gov/pubmed/28640111
http://dx.doi.org/10.1097/MD.0000000000007213

Ejemplares similares